Clinical Trial Update: MSB11022 in Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update for MSB11022 in moderate to severe chronic plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis
• To Severe Plaque Psoriasis

Drugs mentioned

• MSB11022

Snippet

Sponsor: Fresenius Kabi SwissBioSim GmbH | Conditions: Psoriasis, Plaque Type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-19